WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-06-16·Latest →

Thermo Fisher Scientific (TMO) Stock Analysis

OW

TMO Equity Research — OVERWEIGHT — June 2026

← PFEUNH →

Rating date

Jun 16, 2026

55 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

8p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · TMO

Here is the analysis for TMO (Thermo Fisher Scientific) as of June 16, 2026.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Long-term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • Return to top-line growth: After a post-pandemic trough in FY2023–FY2024, Thermo Fisher's revenue re-accelerated to $44.6B in FY2025 (+3.9% YoY), with TTM revenue crossing $45B.
  • Margins trending higher: Operating margin has stabilized at ~19.6% (up from 17.9% in FY2023), demonstrating the benefits of operational efficiency programs and a richer product mix.
  • Consistent earnings growth: Net income rose from $5.995B (FY2023) to $6.704B (FY2025), with diluted EPS growing at a ~7% CAGR over the same period; TTM EPS stands at $18.20.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

TMO Research Note

Full desk note for Jun 16, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

30 min read

WebserviceX · Agentic Research Desk

TMO Equity Research Note

Published Jun 16, 2026 · Desk view OVERWEIGHT · Generated 2026-06-17T07:38:39Z · Maintained by Walter Vijayakumar · Methodology · Track record

TMO Stock Rating Summary

TMO bias

OVERWEIGHT

Horizon

Long-term

TMO key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

TMO catalyst watch

Return to top-line growth: After a post-pandemic trough in FY2023–FY2024, Thermo Fisher's revenue re-accelerated to $44.6B in FY2025 (+3.9% YoY), with TTM revenue crossing $45B.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 8p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-17T07:48:37.978923+00:00.

5D move

—

2026-06-16 → awaiting

Outcome

Awaiting market data

5D trend

-4.24%

Vol (20D ann.)

+36.24%

vs SPY: -6.05%

Close 472.63 → — (USD, vendor closes)

Batch scorecard · 2026-06-16 · TMO

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace ff4f6212…

No QC issues recorded.